Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-27, Stock:ABBV, The news for the past five days is as follows:
2018-06-20: NEWS1: 5 Experimental New Drugs That Could Be Worth $47 Billion.NEWS2: 5 Experimental New Drugs That Could Be Worth $47 Billion.NEWS3: 5 Experimental New Drugs That Could Be Worth $47 Billion.NEWS4: Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks.NEWS5: Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks.NEWS6: Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks.
2018-06-21: NEWS1: ABBV Dividend Yield Pushes Past 4%.NEWS2: ABBV Dividend Yield Pushes Past 4%.NEWS3: XLV, ABBV, AMGN, MDT: ETF Outflow Alert.NEWS4: XLV, ABBV, AMGN, MDT: ETF Outflow Alert.NEWS5: Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street.NEWS6: Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities.
2018-06-22: NEWS1: Is AbbVie Inc (NYSE:ABBV) A Buy At Its Current PE Ratio?.NEWS2: Top Research Reports for Procter & Gamble, AbbVie & IBM.
2018-06-25: NEWS1: Monday 6/25 Insider Buying Report: DOVA, ABBV.NEWS2: Monday 6/25 Insider Buying Report: DOVA, ABBV.NEWS3: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric.NEWS4: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric.NEWS5: IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer.NEWS6: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald&apos;s and General Electric.NEWS7: AbbVie and Calibr announce collaboration for next generation T-cell therapies.
2018-06-26: NEWS1: AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA.NEWS2: AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA.NEWS3: Oversold Conditions For AbbVie (ABBV).NEWS4: Oversold Conditions For AbbVie (ABBV).NEWS5: Google sister company and drug giant chip in another $1 billion to cure age-related diseases.NEWS6: Google sister company and drug giant chip in another $1 billion to cure age-related diseases.NEWS7: Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection.NEWS8: Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection.NEWS9: AbbVie shares rise on $1 bln investment in partnership with Alphabet-backed health company.NEWS10: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS11: AbbVie and Calico Announce Extension of Groundbreaking Collaboration.NEWS12: AbbVie Extends Collaboration With Alphabet-backed Life Sciences Company Calico.NEWS13: AbbVie Extends Collaboration With Alphabet-backed Life Sciences Company Calico.

Answer: Decrease